Cilostazol for Prevention of Recurrent Stroke Trial

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

2,000

Participants

Timeline

Start Date

August 31, 2026

Primary Completion Date

July 31, 2031

Study Completion Date

July 31, 2031

Conditions
Stroke RecurrenceMyocardial InfarctionVascular DeathIschemic StrokeTIA (Transient Ischemic Attack)Stroke (CVA) or Transient Ischemic AttackRecurrent Stroke
Interventions
DRUG

Cilostazol 100 mg

Cilostazol 100 mg tablet taken orally twice daily following an initial 2-week period during which cilostazol is dosed at 100 mg tablet taken orally once daily to maximize tolerability.

DRUG

Placebo

Placebo 100 mg tablet twice taken orally daily following an initial 2-week period during which placebo is dosed at 100 mg taken orally once daily to maximize tolerability.

Trial Locations (1)

94305

Stanford University, Stanford

All Listed Sponsors
collaborator

National Institute of Neurological Disorders and Stroke (NINDS)

NIH

collaborator

Yale University

OTHER

collaborator

University of Cincinnati

OTHER

collaborator

Medical University of South Carolina

OTHER

lead

Stanford University

OTHER